.


Techulon is a life sciences company with a core capability in the development, characterization and synthesis of novel gene delivery techniques for cell-based therapeutics.   In addition to reagent sales to research laboratories, Techulon co-develops delivery platforms for license by pharmaceutical companies.

Techulon’s platform technologies are polymer-based nanoparticles that deliver DNA and RNA into cells with lower cell toxicity and high expression profiles. The company is focused on delivery for therapeutically relevant cells such as primary cells. Applications for this new technology range from research on cellular metabolism to advanced forms of cancer treatment.

Recent News
Techulon platform used for in vivo heart study
Tuesday, January 10, 2012
Techulon’s Platform Demonstrates Effective Non-Viral DNA Delivery for in vivo Cardiac Study. Techulon Glycopolymers Deliver NF-κB Decoy to Mitigate Injury from Cardiac Ischemia.
Techulon featured at VABIO Meeting December 8
Monday, November 28, 2011
Dr. Brett Malone is one of three biotech executives participating in a panel discussion at the VABIO meeting in Richmond, VA, on December 8.
Techulon Expands Coverage in Northern Virginia/Maryland Biotech Corridor
Thursday, October 06, 2011
Local Sales and Technical Support for Glycofect Reagents to Government and University Laboratories
View All  
Upcoming Events
No upcoming events listed.
View All